Biomarkers for Major Depressive Disorder: Economic Considerations

Drug Development Research

Volumn 77, Issue 7, 2016, Pages 374-378

  Bogavac Stanojevic, Natasa ^a   Lakic, Dragana ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

biomarkers; cost effectiveness analysis; major depressive disorder

Indexed keywords

BIOLOGICAL MARKER; ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; MAJOR DEPRESSION; COST BENEFIT ANALYSIS; DEPRESSIVE DISORDER, MAJOR; ECONOMIC MODEL; ECONOMICS; METABOLISM; PATHOPHYSIOLOGY; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY;

ANTIDEPRESSIVE AGENTS; BIOMARKERS; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER, MAJOR; HUMANS; MODELS, ECONOMIC; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; SEROTONIN UPTAKE INHIBITORS;

EID: 84994157910     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21330     Document Type: Article

References (48)

1. Agarwal A, Ressler D, Snyder G. 2015. The current and future state of companion diagnostics. Pharmacogenomics Pers Med 8:99–110.
2. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, de Girolamo G, Graaf R, Demyttenaere K, Gasquet I, et al. 2004. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 109:21–27.
3. Altar CA, Carhart JM, Allen JD, Hall-Flavin DK, Dechairo BM, Winner JG. 2015. Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes. Pharmacogenomics J 15:443–451.
4. Anderson HD, Pace WD, Libby AM, West DR, Valuck RJ. 2012. Rates of 5 common antidepressant side effects among new adult and adolescent cases of depression: a retrospective US claims study. Clin Ther 34:113–123.
5. Atkins D, Briss PA, Eccles M, Flottorp S, Guyatt GH, Harbour RT, Hill S, Jaeschke R, Liberati A, Magrini N, et al. 2005. Systems for grading the quality of evidence and the strength of recommendations II: pilot study of a new system. BMC Health Serv Res 5:25.
6. Biernacka JM, Sangkuhl K, Jenkins G, Whaley RM, Barman P, Batzler A, Altman RB, Arolt V, Brockmöller J, Chen CH, et al. 2015. The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. Transl Psychiatry 5:e553.
7. Bilello JA, Thurmond LM, Smith KM, Pi B, Rubin R, Wright SM, Taub F, Henry ME, Shelton RC, Papakostas GI. 2015. MDDScore: confirmation of a blood test to aid in the diagnosis of major depressive disorder. J Clin Psychiatry 76:e199–e206.
8. Birnbaum HG, Kessler RC, Kelley D, Ben-Hamadi R, Joish VN, Greenberg PE. 2010. Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance. Depress Anxiety 27:78–89.
9. Bojke L, Claxton K, Bravo-Vergel Y, Sculpher M, Palmer S, Abrams K. 2010. Eliciting distributions to populate decision analytic models. Value Health 13:557–564.
10. Brent D, Melhem N, Turecki G. 2010. Pharmacogenomics of suicidal events. Pharmacogenomics 11:793–807.
11. Cumming G. 2008. Replication and p intervals: p values predict the future only vaguely, but confidence intervals do much better. Perspect Psychol Sci 3:286–300.
12. Fabbri C, Di Girolamo G, Serretti A. 2013. Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research. Am J Med Genet B Neuropsychiatr Genet 162B:487–520.
13. Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, Jenkins GD, Reinalda MS, Slager SL, McGrath PJ, Hamilton SP. 2010. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 67:133–138.
14. Greene J, Banasr M, Lee B, Warner-Schmidt J, Duman RS. 2009. Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization. Neuropsychopharmacology 34:2459–2468.
15. Gueorguieva R, Mallinckrodt C, Krystal JH. 2011. Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses. Arch Gen Psychiatry 68:1227–1237.
16. Harbuz M. 2003. Neuroendocrine-immune interactions. Trends Endocrinol Metab 14:51–52.
17. Hendrickx H, McEwen BS, Ouderaa F. 2005. Metabolism, mood and cognition in aging: the importance of lifestyle and dietary intervention. Neurobiol Aging 26:1–5.
18. Herman AP, Bochenek J, Król K, Krawczyńska A, Antushevich H, Pawlina B, Herman A, Romanowicz K, Tomaszewska-Zaremba D. 2016. Central Interleukin-1β Suppresses the Nocturnal Secretion of Melatonin. Mediators Inflamm 2016:2589483. Epub 2016.
19. Hoshaw BA, Malberg JE, Lucki I. 2005. Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res 1037:204–208.
20. Huang TL, Lee CT, Liu YL. 2008. Serum brain-derived neurotrophic factor levels in patients with major depression: effects of antidepressants. J Psychiatr Res 42:521–525.
21. Jakubiak-Lasocka J, Jakubczyk M. 2014. Cost-effectiveness versus Cost-Utility Analyses: What Are the Motives Behind Using Each and How Do Their Results Differ?—A Polish Example. Value Health Regional Issues 4:66–74.
22. Jentsch MC, Van Buel EM, Bosker FJ, Gladkevich AV, Klein HC, Oude Voshaar RC, Ruhé EG, Eisel UL, Schoevers RA. 2015. Biomarker approaches in major depressive disorder evaluated in the context of current hypotheses. Biomark Med 9:277–297.
23. Ji Y, Hebbring S, Zhu H, Jenkins GD, Biernacka J, Snyder K, Drews M, Fiehn O, Zeng Z, Schaid D, et al. 2011. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther 89:97–104.
24. Kapur S, Phillips AG, Insel TR. 2012. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it. Mol Psychiatry 17:1174–1179.
25. Kroenke K, Spitzer RL, Williams JB. 2003. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care 41:1284–1292.
26. Lakhan SE, Vieira K, Hamlat E. 2010. Biomarkers in psychiatry: drawbacks and potential for misuse. Int Arch Med 3:1.
27. Ledley RS, Lusted LB. 1959. Reasoning foundations of medical diagnosis; symbolic logic, probability, and value theory aid our understanding of how physicians reason. Science 130:9–21.
28. Lin E, Chen PS. 2008. Pharmacogenomics with antidepressants in the STAR*D study. Pharmacogenomics 9:935–946.
29. Lopez AD, Murray CJL. 1996. The global burden of disease, 1990–2020. Nat Med 4:1241–1243.
30. Lopresti AL, Maker GL, Hood SD, Drummond PD. 2014. A review of peripheral biomarkers in major depression: The potential of inflammatory and oxidative stress biomarkers. Prog Neuro-Psychopharmacol Biol Psychiatr 48:102–111.
31. Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H. 1997. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 9:853–858.
32. Malberg JE, Platt B, Rizzo SJ, Ring RH, Lucki I, Schechter LE, Rosenzweig-Lipson S. 2007. Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects. Neuropsychopharmacology 32:2360–2368.
33. Mrazek DA, Hornberger JC, Altar CA, Degtiar I. 2014. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996–2013. Psychiatric Serv 65:977–987.
34. O'Brien SM, Scott LV, Dinan TG. 2006. Antidepressant therapy and C-reactive protein levels. Br J Psychiatry 188:449–452.
35. O'Brien SM, Scully P, Fitzgerald P, Scott LV, Dinan TG. 2007. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res 41:326–331. Epub 2006 Jul 25.
36. Papakostas GI, Shelton RC, Kinrys G, Henry ME, Bakow BR, Lipkin SH, Pi B, Thurmond L, Bilello JA. 2013. Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study. Mol Psychiatry 18:332–339.
37. Raison CL, Capuron L, Miller AH. 2006. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 27:24–31.
38. Scarr E, Millan MJ, Bahn S, Bertolino A, Turck CW, Kapur S, Möller HJ, Dean B. 2015. Biomarkers for psychiatry: the journey from fantasy to fact, a report of the 2013 CINP Think Tank. Int J Neuropsychopharmacol 18:pyv042. doi: 10.1093/ijnp/pyv042.
39. Scherf U, Becker R, Chan M, Hojvat S. 2010. Approval of novel biomarkers: FDA's perspective and major requests. Scand J Clin Lab Invest Suppl 242:96–102.
40. Schmidt HD, Shelton RC, Duman RS. 2011. Functional Biomarkers of Depression: Diagnosis, Treatment, and Pathophysiology. Neuropsychopharmacology 36:2375–2394.
41. Smith AJ, Sketris I, Cooke C, Gardner D, Kisely S, Tett SE. 2008. A comparison of antidepressant use in Nova Scotia, Canada and Australia. Pharmacoepidemiol Drug Saf 17:697–706.
42. Sobocki P, Jönsson B, Angst J, Rehnberg C. 2006. Cost of depression in Europe. J Ment Health Policy Econ 9:87–98.
43. Uher R, Perroud N, Ng MYM, Hauser J, Henigsberg N, Maier W, Mors O, Placentino A, Rietschel M, Souery D, et al. 2010. Genomewide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 167:555–564.
44. Uher R, GENDEP Investigators, MARS Investigators, STAR*D Investigators 2013. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry 170:207–217.
45. Van den Bruel A, Cleemput I, Aertgeerts B, Ramaekers D, Buntinx F. 2007. The evaluation of diagnostic tests: evidence on technical and diagnostic accuracy, impact on patient outcome and cost-effectiveness is needed. J Clin Epidemiol 60:1116–1122.
46. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, et al. 2012. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2163–2196.
47. Winner JG, Carhart JM, Altar CA, Goldfarb S, Allen JD, Lavezzari G, Parsons KK, Marshak AG, Garavaglia S, Dechairo BM. 2015. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation. Curr Med Res Opin 31:1633–1643.
48. Young JJ, Silber T, Bruno D, Galatzer-Levy IR, Pomara N, Marmar CR. 2016. Is there Progress? An Overview of Selecting Biomarker Candidates for Major Depressive Disorder. Front Psychiatry 7:72. eCollection 2016.